Rabeprazole Sodium
Product Images NDC 45865-802

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 45865-802). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (802)

Packaging label for Rabeprazole Sodium delayed-release tablets, 20 mg, generic for Aciphex, manufactured by Lupin Ltd. The label shows the product name, strength, dosage form, generic status, lot number, and expiration date, along with usage instructions. The package contains 30 tablets.*

FDA Label Image

Image-01 (Bc740f24 4ae4 4526 Bb34 199d1bd917ff 01)

Chemical structure of rabeprazole sodium, showing its molecular components including a benzimidazole ring, a pyridine ring, and various functional groups such as methoxy and thioether linked to a sodium atom.*

FDA Label Image

Image-02 (Bc740f24 4ae4 4526 Bb34 199d1bd917ff 02)

A line graph showing mean heartburn scores over a 28-day study period for three groups: placebo, Rabeprazole Sodium 10 mg, and Rabeprazole Sodium 20 mg. The vertical axis represents mean heartburn scores from 0 (none) to 4 (very severe), while the horizontal axis indicates study days from -14 to 28. The graph compares symptom changes across the groups over time.*

FDA Label Image

Image03 (Bc740f24 4ae4 4526 Bb34 199d1bd917ff 03)

A line graph showing mean heartburn scores over a 28-day study period with three groups: placebo (n=68), rabeprazole 10 mg (n=64), and rabeprazole 20 mg (n=67). Scores range from 0 (none) to 4 (very severe), plotted against study days before and after treatment initiation (day 0).*

FDA Label Image

Image-04 (Bc740f24 4ae4 4526 Bb34 199d1bd917ff 04)

A line graph showing mean heartburn scores over a 28-day study period comparing placebo and 20 mg rabeprazole (RAB) groups. The y-axis displays mean scores from 0 (none) to 4 (very severe), and the x-axis shows study days from -14 to 28, with a vertical line at day 0 marking treatment start. The placebo group consistently has higher mean scores than the RAB 20 mg group after day 0.*

FDA Label Image

Image05 (Bc740f24 4ae4 4526 Bb34 199d1bd917ff 05)

A line graph showing mean heartburn scores over study days for two groups: placebo (n=58) and RAB 20mg (n=59). The x-axis represents study days from -14 to 28, and the y-axis represents mean heartburn scores from 0 (none) to 4 (very severe). A vertical line marks study day 0. Both groups show a decline in scores after day 0, with the RAB 20mg group generally maintaining lower scores than the placebo group throughout the study period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.